Acute effect of formoterol, salmeterol, albuterol, oxitropium bromide and placebo on FEV1, inspiratory capacity and dyspnoea in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 380s Year: 2001
Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD Source: Eur Respir J 2003; 21: 86-94 Year: 2003
Improvement in dyspnea with fluticasone/salmeterol compared with salmeterol or ipratropium in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004
Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation, dyspnea and exercise tolerance in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 33s Year: 2006
Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD Source: Eur Respir J, 53 (3) 1802049; 10.1183/13993003.02049-2018 Year: 2019
Unaltered perception of dyspnoea during treatment with long-acting β2-agonists Source: Eur Respir J 2001; 18: 269-271 Year: 2001
Six months treatment with salmeterol or ipratropium bromide improves effort tolerance and reduces dyspnoea but does not have any effect on lung function in COPD Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002
Aclidinium bromide improves exercise endurance and decreases exertional dyspnoea in patients with COPD Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010
Formoterol or tiotropium bromide do not influence isolated nocturnal hypoxemia in stable COPD Source: Eur Respir J 2005; 26: Suppl. 49, 294s Year: 2005
Effectiveness of indacaterol and tiotropium in patients with severe dyspnoea Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
The efficacy of long-acting anticholinergic agent, tiotropium bromide on dynamic hyperinflation in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study Source: Eur Respir J 2014; 43: 1599-1609 Year: 2014
Improvement of dyspnoea following of six months treatment with tiotropium but not with salmeterol in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 26s Year: 2001
Effect of the once-daily long-acting bronchodilator combination umeclidinium/vilanterol (UMEC/VI) and bronchodilator monotherapy on dyspnoea as measured by the transitional dyspnoea index (TDI) in COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Differentiation of bronchodilator effects of indacaterol and formoterol by FEV1 and inspiratory capacity (IC) in patients with COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD Source: Eur Respir J 2004; 23: 825-831 Year: 2004
Sleep architecture in COPD patients during salmeterol versus ipratropium bromide treatment Source: Eur Respir J 2004; 24: Suppl. 48, 113s Year: 2004
Effects of tiotropium bromide on bronchial obstruction and exercise tolerance in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 213s Year: 2006
Evaluation of airway sGaw in Japanese COPD patients treated with triple therapy using salmeterol/fluticasone propionate 50/250 and tiotropium bromide Source: International Congress 2015 – COPD: interesting notes Year: 2015
Effect of budesonide/formoterol, budesonide and terbutaline on exercise-induced bronchoconstriction in mild intermittent asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011